EU Accelerated Assessment Tracker
Fast-Track Success For Origin Biosciences’ Rare Disease Drug Fosdenopterin
The filing for Origin Biosciences’ fosdenopterin (Nulibry) is being fast-tracked at the European Medicines Agency. The outcomes of accelerated assessment requests from Janssen and Sanofi for teclistamab and nirsevimab respectively appear not yet to be in the public domain.